<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl2" position="float"><object-id pub-id-type="doi">10.7554/eLife.23813.008</object-id><label>Table 2.</label><caption><p>Genotypes and phenotypes of all patients identified with biallelic MFN2 mutations including p.Arg707Trp; MSL = Multiple Symmetrical Lipomatosis.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.23813.008">http://dx.doi.org/10.7554/eLife.23813.008</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Age, years</th><th>Sex</th><th>MFN2 genotype</th><th>Phenotype(s) (age of onset, years)</th><th valign="top">Comment</th><th>Reference</th></tr></thead><tbody><tr><td>P1</td><td>18</td><td>F</td><td>p.Arg707Trp <break/>R343del</td><td>MSL (&lt;10) <break/>Axonal neuropathy (&lt;10)</td><td valign="top">&#8593;&#8593; lactate <break/>&#8595;&#8595; leptin <break/>&#8595;&#8595; adiponectin</td><td>This study</td></tr><tr><td>P2</td><td>17</td><td>F</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (c.13) <break/>No neuropathy (17)</td><td valign="top">&#8595; adiponectin</td><td>This study</td></tr><tr><td>P3</td><td>16</td><td>M</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (c.13) <break/>No neuropathy (16)</td><td valign="top">&#8595; adiponectin</td><td>This study</td></tr><tr><td>P4</td><td>37</td><td>F</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (c.13) <break/>Likely neuropathy* <break/>Renal tubular dysfunction<sup>&#8224;</sup> (c.13)</td><td valign="top">&#8593;&#8593; lactate <break/>&#8595;&#8595; leptin <break/>&#8595;&#8595; adiponectin</td><td>This study</td></tr><tr><td>Sawyer <italic>et al</italic> Patient 1</td><td>61</td><td>M</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (20&#160;s) <break/>Axonal neuropathy (50&#160;s) <break/>Diabetes (50&#160;s)</td><td valign="top">&#8593; lactate <break/>&#8595;&#8595; leptin <break/>&#8595; adiponectin</td><td>(<xref ref-type="bibr" rid="bib51">Sawyer et al., 2015</xref>)</td></tr><tr><td>Sawyer <italic>et al</italic> Patient 2</td><td>63</td><td>M</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (40&#160;s) <break/>Axonal neuropathy (40s)</td><td valign="top">&#8593; lactate</td><td>(<xref ref-type="bibr" rid="bib45">Nicholson et al., 2008</xref>; <break/><xref ref-type="bibr" rid="bib51">Sawyer et al., 2015</xref>)</td></tr><tr><td>Sawyer <italic>et al</italic> Patient 3</td><td>60</td><td>F</td><td>p.Arg707Trp p.Arg707Trp</td><td>MSL (20&#160;s) <break/>Axonal neuropathy (c.2)</td><td valign="top">&#8593; lactate</td><td>(<xref ref-type="bibr" rid="bib51">Sawyer et al., 2015</xref>)</td></tr><tr><td>Carr <italic>et al</italic> Patient 4/II-1</td><td>44</td><td>M</td><td>p.Arg707Trp <break/>MFN2 ex7-8del</td><td>MSL (not reported) <break/>Axonal neuropathy (2)</td><td valign="top"/><td>(<xref ref-type="bibr" rid="bib9">Carr et al., 2015</xref>)</td></tr><tr><td>Calvo <italic>et al</italic> Patient 6</td><td>19</td><td>M</td><td>p.Arg707Trp p.Gly108Arg</td><td>Axonal neuropathy (&lt;10)</td><td valign="top"/><td>(<xref ref-type="bibr" rid="bib7">Calvo et al., 2009</xref>)</td></tr><tr><td>Calvo <italic>et al</italic> Patient 7</td><td>24</td><td>F</td><td>p.Arg707Trp p.Gly108Arg</td><td>Axonal neuropathy (&lt;10)</td><td valign="top"/><td>(<xref ref-type="bibr" rid="bib7">Calvo et al., 2009</xref>)</td></tr><tr><td>Calvo <italic>et al</italic> Patient 8</td><td>25</td><td>M</td><td>p.Arg707Trp p.Gly108Arg</td><td>Axonal neuropathy (&lt;10)</td><td valign="top"/><td>(<xref ref-type="bibr" rid="bib7">Calvo et al., 2009</xref>)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p>*Based on clinical signs and symptoms.</p></fn><fn id="tblfn5"><p><sup>&#8224;</sup>increased renal protein, magnesium, potassium and calcium with low serum potassium and magnesium; still apparent at 37 years old.</p></fn></table-wrap-foot></table-wrap>